{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:50:19Z","timestamp":1790092219696,"version":"4.0.1"},"reference-count":69,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,14]]},"DOI":"10.14797\/mdcvj.1061","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T12:49:20Z","timestamp":1647262160000},"page":"36-46","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis"],"prefix":"10.14797","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7103","authenticated-orcid":false,"given":"Sajan S.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Stampke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunazi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"16","key":"key20220314084916_B1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"key20220314084916_B2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2559.2007.02658.x","article-title":"Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients","volume":"50","year":"2007","journal-title":"Histopathology"},{"issue":"3","key":"key20220314084916_B3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443200","article-title":"Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy","volume":"135","year":"2016","journal-title":"Acta Haematol"},{"issue":"3","key":"key20220314084916_B4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"key20220314084916_B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light Chain (AL) Amyloidosis: The Journey to Diagnosis","volume":"11","year":"2018","journal-title":"Patient"},{"issue":"1","key":"key20220314084916_B6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000444206","article-title":"The Prevalence and Management of Systemic Amyloidosis in Western Countries","volume":"2","year":"2016","journal-title":"Kidney Dis (Basel)"},{"issue":"10","key":"key20220314084916_B7","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma","volume":"98","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"key20220314084916_B8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"key20220314084916_B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","year":"2016","journal-title":"Amyloid"},{"issue":"12","key":"key20220314084916_B10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","article-title":"Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?","volume":"108","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"Suppl 1","key":"key20220314084916_B11","first-page":"S3","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29 Suppl 1","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"key20220314084916_B12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","year":"2015","journal-title":"Ann Neurol"},{"issue":"3","key":"key20220314084916_B13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/13506129.2018.1503593","article-title":"Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial","volume":"25","year":"2018","journal-title":"Amyloid"},{"issue":"4","key":"key20220314084916_B14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","article-title":"ATTRv amyloidosis Italian Registry: clinical and epidemiological data","volume":"27","year":"2020","journal-title":"Amyloid"},{"issue":"5","key":"key20220314084916_B15","article-title":"Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review","volume":"14","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"6","key":"key20220314084916_B16","article-title":"Transthyretin Cardiac Amyloidosis in Black Americans","volume":"9","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"1","key":"key20220314084916_B17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment","volume":"28","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"6","key":"key20220314084916_B18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11897-016-0311-y","article-title":"New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis","volume":"13","year":"2016","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"key20220314084916_B19","first-page":"159","article-title":"Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease","volume":"117","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"Suppl 2","key":"key20220314084916_B20","first-page":"s30","article-title":"Cardiac amyloidosis","volume":"18","year":"2018","journal-title":"Clin Med (Lond)"},{"issue":"4","key":"key20220314084916_B21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2012.03.001","article-title":"What do I need to know about immunoglobulin light chain (AL) amyloidosis?","volume":"26","year":"2012","journal-title":"Blood Rev"},{"issue":"11","key":"key20220314084916_B22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"key20220314084916_B23","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"key20220314084916_B24","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"key20220314084916_B25","first-page":"1378","article-title":"Magnetic resonance imaging in cardiac amyloidosis","volume":"2","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"key20220314084916_B26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-319-40320-5_15","article-title":"Immunoglobulin Light Chain Systemic Amyloidosis","volume":"169","year":"2016","journal-title":"Cancer Treat Res"},{"issue":"3","key":"key20220314084916_B27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2003.08.043","article-title":"Noninvasive diagnosis of biopsy-proven cardiac amyloidosis","volume":"43","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key20220314084916_B28","first-page":"100519","article-title":"Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist","volume":"28","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"3","key":"key20220314084916_B29","article-title":"Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters","volume":"10","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"38","key":"key20220314084916_B30","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"key20220314084916_B31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","article-title":"Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation","volume":"49","year":"1982","journal-title":"Am J Cardiol"},{"issue":"4","key":"key20220314084916_B32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","year":"2005","journal-title":"Am J Cardiol"},{"issue":"7","key":"key20220314084916_B33","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"key20220314084916_B34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/anec.12036","article-title":"Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis","volume":"18","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"9","key":"key20220314084916_B35","article-title":"Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis","volume":"9","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"8","key":"key20220314084916_B36","article-title":"Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement","volume":"9","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"key20220314084916_B37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"key20220314084916_B38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis","volume":"77","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20220314084916_B39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"12 Suppl 3","key":"key20220314084916_B40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: An update on diagnosis and treatment","volume":"84","year":"2017","journal-title":"Cleve Clin J Med"},{"issue":"10","key":"key20220314084916_B41","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20220314084916_B42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00392-019-01559-y","article-title":"A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis","volume":"109","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"18","key":"key20220314084916_B43","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"issue":"30","key":"key20220314084916_B44","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","year":"2018","journal-title":"Eur Heart J"},{"issue":"23\u201324","key":"key20220314084916_B45","first-page":"742","article-title":"Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement","volume":"132","year":"2020","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"key20220314084916_B46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","year":"2009","journal-title":"Clin Chem"},{"issue":"22","key":"key20220314084916_B47","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20220314084916_B48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","year":"2018","journal-title":"Amyloid"},{"issue":"2","key":"key20220314084916_B49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ajcp\/aqw099","article-title":"Serum Free Light Chain Assay and \u03ba\/\u03bb Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate","volume":"146","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"key20220314084916_B50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1309\/AJCPR2M4EUYNHLGM","article-title":"Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?","volume":"131","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"key20220314084916_B51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1309\/AJCP8VOT5TVLAQBQ","article-title":"Borderline high serum free light chain kappa\/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states","volume":"132","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"key20220314084916_B52","article-title":"Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin","volume":"11","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"4","key":"key20220314084916_B53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/13506129.2021.1904390","article-title":"Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis","volume":"28","year":"2021","journal-title":"Amyloid"},{"issue":"3","key":"key20220314084916_B54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model","volume":"2","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"24","key":"key20220314084916_B55","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"key20220314084916_B56","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ehf2.12511","article-title":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","year":"2019","journal-title":"ESC Heart Fail"},{"issue":"20","key":"key20220314084916_B57","article-title":"Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis","volume":"10","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"key20220314084916_B58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","year":"2005","journal-title":"Circulation"},{"issue":"1 Pt 1","key":"key20220314084916_B59","first-page":"69","article-title":"Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis","volume":"13","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"key20220314084916_B60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic Resonance in Transthyretin Cardiac Amyloidosis","volume":"70","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20220314084916_B61","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization","volume":"14","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"key20220314084916_B62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"key20220314084916_B63","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution","volume":"14","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"key20220314084916_B64","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jcmg.2020.09.009","article-title":"Recipe for Success in Transthyretin Cardiomyopathy: Monoclonal Protein Rule Out, SPECT Imaging, and Genetic Testing","volume":"14","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"key20220314084916_B65","article-title":"Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"13","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"issue":"Suppl 3","key":"key20220314084916_B66","article-title":"The use of a novel method for SPECT\/CT quantification of 99m-Tc-PYP uptake in the evaluation of ATTR cardiac amyloidosis","volume":"22","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"key20220314084916_B67","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples","volume":"95","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"key20220314084916_B68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"key20220314084916_B69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T12:49:59Z","timestamp":1647262199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1061\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,14]]}},"alternative-id":["10.14797\/mdcvj.1061"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1061","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}